Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.24.2.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash Flows From Operating Activities    
Net income $ 2,530 $ 526
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 119 714
Interest accretion expense 30 66
Amortization of deferred financing fees 28
Stock-based compensation 132 349
Bad debt expense reversal (100)
Credit loss expense 26
Change in fair value of note payable 41 142
Amortization on operating lease right of use asset 229 349
Other changes in operating assets and liabilities:    
Accounts receivable (1,249) (497)
Other current assets (101)
Accounts payable (13) 610
Accrued salaries and bonus (726) (329)
Other accrued expenses 337 (138)
Operating lease liabilities (188) (337)
Other long-term liabilities 178 162
Net cash provided by operating activities 1,346 1,544
Cash Flows From Investing Activity    
Working capital adjustment on sale of Interpace Pharma Solutions (117)
Purchase of property and equipment (225) (176)
Net cash used in investing activities (225) (293)
Cash Flows From Financing Activities    
Payments made on note payable (2,600)
Payments on line of credit (1,000)
Net cash used in financing activities (2,600) (1,000)
Net (decrease) increase in cash, cash equivalents and restricted cash (1,479) 251
Cash, cash equivalents and restricted cash from continuing operations– beginning 3,498 4,828
Cash, cash equivalents and restricted cash from discontinued operations– beginning
Cash, cash equivalents and restricted cash – beginning 3,498 4,828
Cash, cash equivalents and restricted cash from continuing operations– ending 2,019 5,079
Cash, cash equivalents and restricted cash from discontinued operations– ending
Cash, cash equivalents and restricted cash – ending $ 2,019 $ 5,079